Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

47 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-23

Study Completion Date

2017-09-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the effectiveness and safety of osimertinib treatment in a real world setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

NCT03219970

Non-small Cell Lung Cancer

COMPLETED

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

NCT03485326

Non-small Cell Lung Cancer

COMPLETED

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

NCT07295821

Lung Cancer

NOT_YET_RECRUITING PHASE2

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

NCT05513664

Locally Advanced or Metastatic Non-Small Cell Lung Cancer EGFR Exon20 Insertion Mutations

UNKNOWN

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519

Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The current study will not only assess the effectiveness of osimertinib treatment in a real world setting, but will also help us to understand the real-world testing patterns among T790M mutation positive locally advanced or metastatic NSCLC patients who have progressed after EGFR TKI treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

T790M Positive NSCLC Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EGFR T790M Patients

Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI

osimertinib

Intervention Type DRUG

Oral dose of 80mg once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

osimertinib

Oral dose of 80mg once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Above 18 years of age;
* Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
* Confirmed T790M mutation
* Progressed on previous EGFR TKI treatment. Patients may have also received additional lines of treatment
* Received osimertinib treatment in the participating site between May 1st and Oct 31st 2016